Recent reports indicate mixed outcomes for
Zimmer Biomet Holdings. The healthcare company made several executive appointments, including
David DeMartino as Senior Vice President, Investor Relations, and
Devdatt Kurdikar among the Board of Directors. The company also announced plans to acquire
OrthoGrid Systems and entered partnership deals with
THINK Surgical and
RevelAi Health. Zimmer Biomet achieved FDA clearance for the ROSA® Shoulder System and reported various quarterly earnings. Despite robust demand for
knee and
hip devices and a significant stake acquired by Principal Financial Group, several investors and traders report a loss. Ratings are varied, with Evercore ISI giving an in-line rating, while TD Cowen recently set a new price of $119.00. Despite achieving above market growth,
Zimmer Biomet faced critical software switch impact resulting in a revenue warning and consequent fall in stock prices.
Zimmer Biomet Holdings ZBH News Analytics from Wed, 11 Oct 2023 07:00:00 GMT to Sun, 08 Sep 2024 10:51:18 GMT -
Rating 5
- Innovation 4
- Information 7
- Rumor 5
